|
AstraZeneca PLC on Tuesday said eplontersen, its candidate for a form of hereditary polyneuropathy, demonstrated significant positive results in a phase 3 trial interim analysis.
Based on the 35-week results, AstraZeneca is seeking regulatory approval and plans to file a new drug application with the US Food & Drug Administration in 2022, it announced.
Polyneuropathy is a disease under which peripheral nerves malfunction, which can impair the whole body and lead to loss of sensation and respiratory failure.
The trial showed ‘treatment with eplontersen significantly improved patient-reported quality of life versus external placebo group. In the trial, eplontersen demonstrated a favourable safety and tolerability profile with no specific concerns,’ the Cambridge-based pharmaceutical company explained.
AstraZeneca shares were 0.2% lower at 10,030.00 pence each in London on Tuesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
